Does the media refer more to LMAT or GKOS?

In the previous week, Glaukos had 6 more articles in the media than LeMaitre Vascular. MarketBeat recorded 11 mentions for Glaukos and 5 mentions for LeMaitre Vascular. Glaukos' average media sentiment score of 0.65 beat LeMaitre Vascular's score of 0.41 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LQDA or LMAT?

LeMaitre Vascular has higher revenue and earnings than Liquidia. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 41.10 -$68.92M $0.14 522.67 LeMaitre Vascular $249.60M 8.95 $57.73M $2.71 36.09

Does the media favor LQDA or LMAT?

In the previous week, Liquidia had 5 more articles in the media than LeMaitre Vascular. MarketBeat recorded 10 mentions for Liquidia and 5 mentions for LeMaitre Vascular. Liquidia's average media sentiment score of 0.54 beat LeMaitre Vascular's score of 0.41 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LMAT or BLCO?

In the previous week, Bausch + Lomb had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 7 mentions for Bausch + Lomb and 5 mentions for LeMaitre Vascular. Bausch + Lomb's average media sentiment score of 0.56 beat LeMaitre Vascular's score of 0.41 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LMAT or STVN?

LeMaitre Vascular currently has a consensus target price of $112.60, indicating a potential upside of 15.13%. Given LeMaitre Vascular's higher possible upside, equities analysts clearly believe LeMaitre Vascular is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LeMaitre Vascular 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83

Does the media prefer LMAT or STVN?

In the previous week, LeMaitre Vascular had 4 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for LeMaitre Vascular and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.73 beat LeMaitre Vascular's score of 0.41 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to LMAT or LIVN?

In the previous week, LeMaitre Vascular had 2 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for LeMaitre Vascular and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.52 beat LeMaitre Vascular's score of 0.41 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

LeMaitre Vascular (LMAT) Competitors

$97.80 -2.49 (-2.48%)

As of 10:17 AM Eastern

Compare

LMAT vs. GKOS, LQDA, BLCO, STVN, and LIVN

Should you buy LeMaitre Vascular stock or one of its competitors? MarketBeat compares LeMaitre Vascular with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LeMaitre Vascular include Glaukos (GKOS), Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does LeMaitre Vascular compare to Glaukos?

LeMaitre Vascular (NASDAQ:LMAT) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

LeMaitre Vascular has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.95	$57.73M	$2.71	36.09
Glaukos	$551.35M	16.17	-$187.69M	-$3.28	N/A

LeMaitre Vascular presently has a consensus price target of $112.60, indicating a potential upside of 15.13%. Glaukos has a consensus price target of $151.77, indicating a potential upside of 0.01%. Given LeMaitre Vascular's higher possible upside, equities analysts plainly believe LeMaitre Vascular is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

LeMaitre Vascular has a net margin of 24.35% compared to Glaukos' net margin of -34.34%. LeMaitre Vascular's return on equity of 15.36% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Glaukos	-34.34%	-6.92%	-5.25%

In the previous week, Glaukos had 6 more articles in the media than LeMaitre Vascular. MarketBeat recorded 11 mentions for Glaukos and 5 mentions for LeMaitre Vascular. Glaukos' average media sentiment score of 0.65 beat LeMaitre Vascular's score of 0.41 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

LeMaitre Vascular and Glaukos tied by winning 8 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Liquidia?

Liquidia (NASDAQ:LQDA) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

LeMaitre Vascular has a net margin of 24.35% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
LeMaitre Vascular	24.35%	15.36%	9.78%

Liquidia currently has a consensus target price of $68.88, indicating a potential downside of 5.88%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 15.13%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Liquidia had 5 more articles in the media than LeMaitre Vascular. MarketBeat recorded 10 mentions for Liquidia and 5 mentions for LeMaitre Vascular. Liquidia's average media sentiment score of 0.54 beat LeMaitre Vascular's score of 0.41 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has higher revenue and earnings than Liquidia. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	41.10	-$68.92M	$0.14	522.67
LeMaitre Vascular	$249.60M	8.95	$57.73M	$2.71	36.09

Liquidia has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Summary

Liquidia beats LeMaitre Vascular on 10 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to Bausch + Lomb?

LeMaitre Vascular (NASDAQ:LMAT) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LeMaitre Vascular presently has a consensus price target of $112.60, suggesting a potential upside of 15.13%. Bausch + Lomb has a consensus price target of $18.00, suggesting a potential upside of 11.99%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, equities analysts plainly believe LeMaitre Vascular is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

LeMaitre Vascular has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.95	$57.73M	$2.71	36.09
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A

LeMaitre Vascular has a net margin of 24.35% compared to Bausch + Lomb's net margin of -4.21%. LeMaitre Vascular's return on equity of 15.36% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, Bausch + Lomb had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 7 mentions for Bausch + Lomb and 5 mentions for LeMaitre Vascular. Bausch + Lomb's average media sentiment score of 0.56 beat LeMaitre Vascular's score of 0.41 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

LeMaitre Vascular beats Bausch + Lomb on 11 of the 15 factors compared between the two stocks.

How does LeMaitre Vascular compare to Stevanato Group?

LeMaitre Vascular (NASDAQ:LMAT) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

In the previous week, LeMaitre Vascular had 4 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for LeMaitre Vascular and 1 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.73 beat LeMaitre Vascular's score of 0.41 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

84.6% of LeMaitre Vascular shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Stevanato Group has higher revenue and earnings than LeMaitre Vascular. Stevanato Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.95	$57.73M	$2.71	36.09
Stevanato Group	€1.34B	4.48	€158.21M	€0.59	33.64

LeMaitre Vascular currently has a consensus target price of $112.60, indicating a potential upside of 15.13%. Given LeMaitre Vascular's higher possible upside, equities analysts clearly believe LeMaitre Vascular is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

LeMaitre Vascular has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

LeMaitre Vascular has a net margin of 24.35% compared to Stevanato Group's net margin of 11.76%. LeMaitre Vascular's return on equity of 15.36% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Stevanato Group	11.76%	10.27%	6.08%

Summary

LeMaitre Vascular beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to LivaNova?

LeMaitre Vascular (NASDAQ:LMAT) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, LeMaitre Vascular had 2 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for LeMaitre Vascular and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.52 beat LeMaitre Vascular's score of 0.41 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LeMaitre Vascular has a net margin of 24.35% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
LivaNova	7.48%	16.48%	7.59%

LeMaitre Vascular currently has a consensus price target of $112.60, indicating a potential upside of 15.13%. LivaNova has a consensus price target of $80.75, indicating a potential upside of 1.16%. Given LeMaitre Vascular's higher possible upside, equities analysts plainly believe LeMaitre Vascular is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LeMaitre Vascular has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

LeMaitre Vascular has higher earnings, but lower revenue than LivaNova. LeMaitre Vascular is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.95	$57.73M	$2.71	36.09
LivaNova	$1.39B	3.16	-$242.47M	$1.95	40.93

Summary

LeMaitre Vascular and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

Get LeMaitre Vascular News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMAT vs. The Competition

Export

Metric	LeMaitre Vascular	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.24B	$8.30B	$6.76B	$12.50B
Dividend Yield	0.97%	2.54%	2.68%	8.00%
P/E Ratio	36.10	15.70	26.93	24.41
Price / Sales	8.95	7.03	586.18	117.36
Price / Cash	35.40	18.40	29.22	49.36
Price / Book	5.64	3.57	10.94	6.33
Net Income	$57.73M	$228.19M	$3.58B	$330.66M
7 Day Performance	-7.47%	-3.16%	-2.10%	-0.66%
1 Month Performance	6.35%	-1.51%	3.21%	-0.14%
1 Year Performance	16.31%	-3.67%	26.34%	20.16%

LeMaitre Vascular Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMAT LeMaitre Vascular	3.9633 of 5 stars	$97.80 -2.5%	$112.60 +15.1%	+19.8%	$2.24B	$249.60M	36.10	490
GKOS Glaukos	1.6925 of 5 stars	$147.30 -0.9%	$150.62 +2.3%	+47.3%	$8.65B	$507.44M	N/A	1,094	Analyst Forecast Insider Trade
LQDA Liquidia	2.6615 of 5 stars	$79.76 +0.7%	$68.88 -13.6%	+405.4%	$7.08B	$158.32M	568.50	50
BLCO Bausch + Lomb	3.7159 of 5 stars	$17.22 +0.7%	$17.83 +3.5%	+17.1%	$6.14B	$5.10B	N/A	13,000
STVN Stevanato Group	2.747 of 5 stars	€19.17 -0.6%	N/A	-21.4%	€5.81B	€1.20B	32.54	6,010

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMAT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does LeMaitre Vascular compare to Glaukos?

Summary

How does LeMaitre Vascular compare to Liquidia?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Summary

How does LeMaitre Vascular compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does LeMaitre Vascular compare to Glaukos?

Which has stronger earnings and valuation, LMAT or GKOS?

Do analysts recommend LMAT or GKOS?

Is LMAT or GKOS more profitable?

Does the media refer more to LMAT or GKOS?

Which has more risk & volatility, LMAT or GKOS?

Do institutionals & insiders have more ownership in LMAT or GKOS?

Summary

How does LeMaitre Vascular compare to Liquidia?

Is LQDA or LMAT more profitable?

Do analysts rate LQDA or LMAT?

Do institutionals and insiders believe in LQDA or LMAT?

Does the media favor LQDA or LMAT?

Which has better earnings and valuation, LQDA or LMAT?

Which has more volatility and risk, LQDA or LMAT?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Do insiders & institutionals believe in LMAT or BLCO?

Do analysts prefer LMAT or BLCO?

Which has preferable earnings & valuation, LMAT or BLCO?

Is LMAT or BLCO more profitable?

Does the media prefer LMAT or BLCO?

Which has more volatility and risk, LMAT or BLCO?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Does the media prefer LMAT or STVN?

Do insiders and institutionals have more ownership in LMAT or STVN?

Which has better valuation & earnings, LMAT or STVN?

Do analysts recommend LMAT or STVN?

Which has more risk & volatility, LMAT or STVN?

Is LMAT or STVN more profitable?

Summary

How does LeMaitre Vascular compare to LivaNova?

Does the media refer more to LMAT or LIVN?

Is LMAT or LIVN more profitable?

Do analysts recommend LMAT or LIVN?

Do institutionals & insiders believe in LMAT or LIVN?

Which has more volatility & risk, LMAT or LIVN?

Which has higher valuation and earnings, LMAT or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools